Most Read Articles
Natalia Reoutova, 3 days ago

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Pearl Toh, 28 Aug 2019
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.
Audrey Abella, 28 Aug 2019
A pooled analysis of six trials failed to show noninferiority of a 3-month regimen to a 6-month regimen of oxaliplatin-based chemotherapy for patients with high-risk, stage II colorectal cancer (CRC).

Clinical genetic testing in HBOC syndrome

Dr Joslyn Ngu
04 Dec 2017

Hereditary breast and ovarian cancer (HBOC) syndrome, which is primarily caused by BRCA1 and BRCA2 mutations, make up 8 to 10 percent of all breast cancers, says a senior consultant.

The inheritance pattern is autosomal dominant and rarely de novo, said Associate Professor Joanne Ngeow Yuen Yie, head of the Cancer Genetics Service, National Cancer Centre Singapore and senior consultant in Division of Medical Oncology at the same centre.

In those with HBOC syndrome, the risk of developing breast cancer by age 70 is 56 to 87 percent, and the risk of developing ovarian cancer is 27 to 44 percent by the age of 75, she said. Besides elevated risk of breast and ovarian cancer, those with HBOC syndrome is also at a higher risk of developing prostate cancer, melanoma and pancreatic cancer.

Genetic counselling for HBOC syndrome should be provided to those with a personal history of or close family member with, for instance: ovarian, fallopian tube or primary peritoneal cancer; breast cancer diagnosed before the age of 50; and men with breast cancer, explained Ngeow.

Currently, there are more than 400 hereditary cancer syndromes identified and the number will increase, she said. Pre- and post-genetic test counselling are important so there is shared decision-making for gene-directed management.

Panel testing will be the way forward. As it is new, there will be pitfalls and clinicians need to be aware of them, Ngeow concluded.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 3 days ago

A retrospective analysis of seven clinical trials demonstrated that neratinib-based therapy is safe and effective in Asian patients with metastatic HER2-positive breast cancer.

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Pearl Toh, 28 Aug 2019
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.
Audrey Abella, 28 Aug 2019
A pooled analysis of six trials failed to show noninferiority of a 3-month regimen to a 6-month regimen of oxaliplatin-based chemotherapy for patients with high-risk, stage II colorectal cancer (CRC).